BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Archus Orthopedics, Inc. Completes One Hundred TFAS(R) Implants


8/16/2007 9:45:27 AM

REDMOND, Wash., Aug. 16 /PRNewswire/ -- Archus Orthopedics, Inc. today announced that over one hundred patients worldwide have now been successfully implanted with the company's Total Facet Arthroplasty System(R) or "TFAS(R)". The company indicated that the vast majority of TFAS cases have been performed in the United States in an ongoing IDE study approved by the U.S. Food and Drug Administration.

TFAS is a novel spinal implant designed to treat spinal stenosis, a condition in which degenerative changes in the facet joints result in compression of spinal nerves producing neurological symptoms in the legs. Traditionally, patients with moderate to severe spinal stenosis undergo decompressive laminectomy surgery, which is often accompanied by spinal fusion. The TFAS replaces the degenerative facet joints with a prosthetic joint implant intended to restore stability and normal motion to the spine, eliminating the need for fusion.

"This is an important milestone for facet arthroplasty and for Archus Orthopedics," said Jim Fitzsimmons, chairman and chief executive officer. "Our study results to date are demonstrating clinically significant improvement in patient symptoms and function. With longest patient follow-up now well over two years, we are confident that this is a durable implant and procedure," he added.

In addition to TFAS, Archus is developing a suite of products to address other important clinical applications for facet joint replacement. "We expect to report first human implants of these devices this year," said Fitzsimmons.

About Archus Orthopedics

Founded in July 2001, Archus Orthopedics is a privately held company developing a family of reconstructive implants to treat a variety of spine disorders resulting from degenerative changes in the facet joints. Archus has received venture capital funding from MPM Capital, InterWest Partners, Polaris Venture Partners and Johnson & Johnson Development Corporation, in cooperation with DePuy Spine.

Archus Orthopedics, Inc.

CONTACT: Jim Fitzsimmons, Chairman and Chief Executive Officer of ArchusOrthopedics, Inc., +1-425-284-3650, jfitzsimmons@archususa.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES